HBK Investments L P acquired a new position in Becton Dickinson and Co (NYSE:BDX) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 287,539 shares of the medical instruments supplier’s stock, valued at approximately $61,551,000. Becton Dickinson and accounts for about 0.6% of HBK Investments L P’s portfolio, making the stock its 11th biggest holding. HBK Investments L P owned approximately 0.11% of Becton Dickinson and as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in BDX. Raymond James Financial Services Advisors Inc. lifted its stake in Becton Dickinson and by 6.6% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 141,760 shares of the medical instruments supplier’s stock worth $27,778,000 after acquiring an additional 8,719 shares during the period. Smith Moore & CO. lifted its stake in Becton Dickinson and by 35.7% in the third quarter. Smith Moore & CO. now owns 1,982 shares of the medical instruments supplier’s stock worth $388,000 after acquiring an additional 521 shares during the period. United Asset Strategies Inc. purchased a new stake in Becton Dickinson and in the third quarter worth about $338,000. Daiwa Securities Group Inc. raised its holdings in Becton Dickinson and by 42.5% in the third quarter. Daiwa Securities Group Inc. now owns 9,137 shares of the medical instruments supplier’s stock worth $1,790,000 after purchasing an additional 2,727 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund raised its holdings in Becton Dickinson and by 9.6% in the third quarter. Oregon Public Employees Retirement Fund now owns 24,278 shares of the medical instruments supplier’s stock worth $4,757,000 after purchasing an additional 2,130 shares in the last quarter. 83.37% of the stock is owned by institutional investors.
In other news, VP John E. Gallagher sold 5,346 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $226.08, for a total transaction of $1,208,623.68. Following the transaction, the vice president now owns 9,391 shares in the company, valued at $2,123,117.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP James W. Borzi sold 4,048 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $224.98, for a total transaction of $910,719.04. Following the transaction, the executive vice president now owns 5,334 shares in the company, valued at approximately $1,200,043.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 279,231 shares of company stock worth $60,895,317. Corporate insiders own 1.00% of the company’s stock.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter in the prior year, the company posted $2.33 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. sell-side analysts forecast that Becton Dickinson and Co will post 10.94 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be issued a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 annualized dividend and a dividend yield of 1.33%. Becton Dickinson and’s dividend payout ratio (DPR) is currently 229.01%.
A number of equities analysts have commented on BDX shares. Argus boosted their target price on shares of Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a report on Thursday, December 14th. They noted that the move was a valuation call. Deutsche Bank set a $260.00 target price on shares of Becton Dickinson and and gave the stock a “buy” rating in a report on Friday, December 29th. Evercore ISI started coverage on shares of Becton Dickinson and in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 target price for the company. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 target price for the company in a report on Wednesday, January 3rd. Finally, KeyCorp started coverage on shares of Becton Dickinson and in a report on Friday, January 5th. They issued an “overweight” rating and a $260.00 target price for the company. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $238.00.
WARNING: “HBK Investments L P Acquires New Position in Becton Dickinson and Co (BDX)” was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/03/12/hbk-investments-l-p-acquires-new-position-in-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.